Fibrillation, Atrial Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of SB 207266 in Patients With Symptomatic Persistent Atrial Fibrillation (AF)
The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 | |
| Terminated |
NCT00437242 -
Odiparcil QT Definitive Study
|
Phase 1 | |
| Completed |
NCT00402363 -
Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation
|
Phase 3 | |
| Completed |
NCT00240643 -
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
|
Phase 2 | |
| Withdrawn |
NCT03401931 -
Artificial Intelligence Use for the Detection of Atrial Fibrillation Drivers
|
||
| Completed |
NCT04537507 -
Atrial Fibrillation and Non-obstructive Coronary Lesions
|
||
| Completed |
NCT04761315 -
Detecting Atrial Fibrillation in Patients With an Embolic Stroke of Undetermined Source (From the DAF-ESUS Registry)
|
||
| Not yet recruiting |
NCT06200311 -
Atrial Fibrillation (AF) Ablation to Prevent Disease Progression of AF-induced Atrial Cardiomyopathy in Women and Men
|
N/A | |
| Completed |
NCT00911300 -
Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm
|
Phase 2 |